Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXDX-105 for RET+ NSCLC and BRAF+ Ovarian Cancer
NCT03784378Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of agerafenib in non-small cell lung cancer (NSCLC) and ovarian cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Evaluation during treatment/intervention at 5 years. Started Dec 2018; status: completed.
02
Drugs
agerafenib
03
Conditions
non-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT03784378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784378.